Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases.
10.4174/jkss.2013.85.4.154
- Author:
Ji Yeon KIM
1
;
Jin Soo KIM
;
Moo Jun BAEK
;
Chang Nam KIM
;
Won Jun CHOI
;
Dong Kook PARK
;
Hwan NAMGUNG
;
Sang Chul LEE
;
Sang Jeon LEE
Author Information
1. Department of Surgery, Chungnam National University School of Medicine, Daejeon, Korea.
- Publication Type:Clinical Trial ; Multicenter Study ; Original Article
- Keywords:
Colorectal cancer;
Neoadjuvant therapy;
Metastasis;
Chemotherapy
- MeSH:
Camptothecin;
Colorectal Neoplasms;
Humans;
Liver;
Neoadjuvant Therapy;
Neoplasm Metastasis;
Prospective Studies;
Tertiary Care Centers
- From:Journal of the Korean Surgical Society
2013;85(4):154-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study evaluated the efficacy of neoadjuvant chemotherapy combining 5-flurouracil/folinic acid with irinotecan (FOLFIRI) in colorectal multiple liver metastases regardless of resectability. METHODS: Forty-four patients with multiple (at least two) colorectal liver metastases were enrolled at seven tertiary referral hospitals between May 2007 and September 2010. All patients received the FOLFIRI chemotherapeutic regimen. Response to chemotherapy was assessed after three cycles (6 weeks) and once more after six cycles (12 weeks) of treatment. RESULTS: Objective response was noted in 27 patients (61.4%) and 4 patients (9.1%) had progressive disease. Of 44 patients, 10 patients (22.7%) underwent curative surgery (R0 resection) and 34 patients did not receive R0 resection. Grades 3 to 4 hematological toxicity was noted in 12 patients (27.3%) and grades 3 to 4 nonhematologic toxicity was identified in 5 patients (11.4%). CONCLUSION: FOLFIRI chemotherapy as a neoadjuvant chemotherapy for multiple colorectal liver metastases regardless of resectability demonstrated the possibility of R0 resection, high rate of objective response, and tolerable toxicities in this study.
